Reply to S. Kusumoto et al.
Taipei Veterans General Hospital; Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Yi-Hsiang
YH
Huang
Han-Chieh
HC
Lin
Shou-Dong
SD
Lee
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006509:Hepatitis B / Q000821:virology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D000069283:Rituximab; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*
D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D000069283:Rituximab; C413685:entecavir; D006147:Guanine